Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1177-1182

  Hartmann, Jörg Thomas ^a   Kanz, Lothar ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Advanced gastrointestinal cancer; Colorectal carcinoma; Continuous infusion; Gastric cancer; Mitomycin C; Salvage chemotherapy

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; PACLITAXEL; PREDNISOLONE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL CARCINOMA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0034054141     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Dorr RT: New findings in the pharmacokinetic, metabolic and drug-resistance aspects of mitomycin C. Semin Oncol 15: 32-41, 1488.
2. Doroshow JH: Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proc Natl Acad Sci USA 81: 4514-4518, 1986.
3. Dusre L, Rayagopalan S, Eliot HM, et al: DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line for mitomycin C and its analogues. Cancer Res 50: 648-652, 1990.
4. Pritsos CA and Sarotelli AC: Generation of reactive oxygen radicals through bioactivation of mitomycin C antibiotics. Cancer Res 46: 3528-3532, 1986.
5. Moertel CG: Clinical management of advanced gastrointestinal cancer. Cancer 36: 675-682, 1975.
6. Reitemeier RJ, Moertel CG, Hahn RG: Combination chemotherapy in gastrointestinal cancer. Cancer Res 30: 1425-1428, 1970.
7. Comis R: Integration of chemotherapy into combined modality treatment of solid tumours. Cancer Treat Rev 1: 22-33, 1974.
8. Machover D, Goldschmidt E, Chollet P: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685-696, 1986.
9. Löffler TM, Weber FW, Hausamen TU: Klinische Erfahrungen mit der ambulanten Dauerinfusion von Mitomycin C. Tumordiagnostik & Therapie 12: 132-135, 1992.
10. Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Müller C, Seeber S, Kanz L and Bokemeyer C: Phase II study of continuous 120 hours-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. AntiCancer Drugs 9: 427-431, 1998.
11. Kaplan EL, Maier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
12. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959.
13. Moertel CG, Reitemeier RJ, Hahn RG: Mitomycin C in advanced gastrointestinal cancer. J Am Med Assoc 204: 1045-1048, 1968.
14. Allum WH, Hallissey MT, Kelly A: Adjuvant chemotherapy in operable gastric cancer. Lancet 1(8638): 571-574, 1989.
15. Ansfield F: Clinical study of mitomycin-C (NSC 26980) in colorectal cancer. Cancer Chemother Rep 53: 287-289, 1969.
16. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 4: 1128-1135, 1996.
17. Shimada, Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivate, in metastatic colorectal cancer. J Clin Oncol 11: 909-913, 1993.
18. Rougier P, Bugat R, Douillard JY, Culine S, Sue E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997.
19. van Cutsem E, Cunningham D, Huinink WWT, Punt CJA, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Herat P, Bleiberg H. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 35: 54-59, 1999.
20. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Steinke B, Weber W, Burkhard O, Zoller A, Pfitzner J, Subert R, Kriebel R, Hossfeld DK: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 5: 233-237, 1994.
21. Jäger, E, Klein O, Wächter B, Müller B, Braun U, Knuth A: High-dose 5-fluorouracil (5-FU) and folinic in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study. Eur J Cancer 31A: 1717 (letter), 1995.
22. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell S, Morell L, Feun L, Savaraj N, Livingstone A: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-630, 1991.
23. Hartmann JT, Könne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C: Is continuous 24 hour-infusion of 5-fluorouracil and high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer - Results from a phase II study. Oncology 55: 320-325, 1998.
24. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al: A chronopharmacologic phase II clinical trial with 5-fluorouracil, foloinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69: 893-900, 1992.
25. DeGramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, Raymond E, Moreau S, LeBail N, Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
26. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendivillc J, Watson M, Massey A, Popescu R, Oates J: A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995-1001, 1997.
27. Becker K, Rinas U, Weidmann B, et al: High-dose 5-fluorouracil/ folinic acid plus mitomycin C (MMC) in patients with refractory colorectal cancer. Proc Am Soc Clin Oncol 16: 283 (abstr 1004), 1997.
28. Comis R: Integration of chemotherapy into combined modality treatment of solid tumours. Cancer Treat Rev 1: 22-33, 1974.
29. Wilke H, Preusser P, Fink U, Achterrath W, Mayer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Gerlings H: New developments in the treatment of gastric carcinoma. Semin Oncol 17: 61-70 (suppl 2), 1990.
30. Lerner A, Gonin R, Steele GD Jr, Mayer RJ: Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 10: 536-540, 1992.
31. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541-548, 1992.
32. Stahl M, Vanhoefer U, Fink U, Korn M, Eigler FW, Siewert JR, Seeber S, Wilke H. Phase II study of weekly high-dose 5-fluorouracil and folinic acid plus biweekly alternating cisplatin and epirubicin (FUFACE) in patients with advanced gastric carcinoma. Onkologie 19: 416-418, 1996.
33. Roelofs EJM, Wagener DJTh, Conroy Th, Wils J, Burghouts J Th, Fickers M, de Graeff A, Lalisang F, Paillot B: Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer. Ann Oncol 4: 426-428, 1993.
34. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L, Kanz L: Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Sem Oncol 24: 96-100 (Suppl. 19), 1997.
35. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17: 319-323, 1999,
36. Vanhoefer U, Wilke H., Weh HJ, Clemens M, Harstrick A, Stahl M, Hossfeld DK, Seeber S. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 5: 850-851, 1994.
37. Di Bartolomeo M, Bajetta E, Somma L, Carnaghi C, Bandieri E, Del Vecchio M, Stampino CG, Buzzoni R: Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology 53: 54-57, 1996.
38. Wilke H, Vanhoefer U, Harstrick A: Phase II study of doxetaxel as salvage chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 17: 305 (abstr. 1177), 1948.
39. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G: Phase II study of paclitaxel in pretreated advanced gastric cancer. AnticancerDrugs 9: 307-310, 1998.
40. Rougier P, van Pottelsberghe C, Kok T, Paillot B, Wagener T, De Greve J, Fabri MC, Gerard B, Van Glabbeke M, Bleiberg H: Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG. Eur J Cancer 32A: 1432-1433, 1996.